Ponatinib Monotherapy in Adult Patients with Relapsed or Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia: A Real-World Retrospective Analysis Including Measurable Residual Disease Relapse
Ponatinib achieved an acceptable CR rate and MRD response in R/R Ph-positive ALL, but long-term survival remained poor despite allo-HCT. These results support earlier use of ponatinib in the salvage setting and highlight the need for combination strategies to overcome the limited durability of monotherapy in patients with R/R Ph-positive ALL.
Authors
- Kyoung Il Min (ORCID: https://orcid.org/0000-0002-8089-3800)
- Seok‐Goo Cho (ORCID: https://orcid.org/0000-0002-5429-4839)
- Byung‐Sik Cho (ORCID: https://orcid.org/0000-0002-4524-6616)
- Jae‐Ho Yoon (ORCID: https://orcid.org/0000-0002-2145-9131)
- Gi June Min (ORCID: https://orcid.org/0000-0001-7636-4693)
- Daehun Kwag (ORCID: https://orcid.org/0000-0003-3353-882X)
- Sung‐Eun Lee (ORCID: https://orcid.org/0000-0002-9810-2050)
- Yoo‐Jin Kim (ORCID: https://orcid.org/0000-0001-6653-2956)
- Sung‐Soo Park (ORCID: https://orcid.org/0000-0002-8826-4136)
- Hee‐Je Kim (ORCID: https://orcid.org/0000-0003-4098-3366)
- Chang‐Ki Min (ORCID: https://orcid.org/0000-0002-1940-0392)
- Silvia Park
- Ki-Seong Eom
Institutions
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1159/000548544
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00